Healthcare Services

Liquid Biopsy For Cancer Diagnostics Market Size Outlook and Demand Growth Across 2026–2030

April 2, 2026April 15, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Size Increase Is Anticipated For The Liquid Biopsy For Cancer Diagnostics Market Over The 2026–2030 Period?

The liquid biopsy for cancer diagnostics market size has undergone rapid expansion in recent years. It is anticipated to increase from $10.75 billion in 2025 to $12.52 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 16.4%. The historical growth can be attributed to several factors including the constraints of tissue biopsy procedures, an increasing prevalence of lung and breast cancer, the early embrace of molecular cancer diagnostics, a heightened necessity for early-stage cancer detection, and the growing volume of clinical research in oncology diagnostics.

The liquid biopsy for cancer diagnostics market is anticipated to experience significant expansion over the coming years, projected to reach $22.99 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 16.4%. This projected growth is largely driven by factors such as the broader integration of liquid biopsy into standard cancer screening procedures, an increasing emphasis on individualized cancer treatments, its greater utilization for monitoring treatment effectiveness, escalating financial commitments in cancer diagnostics, and its expanding application in addressing gastrointestinal and ovarian cancers. Key trends expected during this period involve the increasing embrace of liquid biopsy for diagnosing lung cancer, a surge in the application of blood-based methods for cancer screening, a heightened need for continuous cancer monitoring, the proliferation of liquid biopsy applications across a wider spectrum of cancer types, and a growing medical inclination towards less invasive diagnostic techniques.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12205&type=smp

Which Major Factors Are Driving The Expansion Of The Liquid Biopsy For Cancer Diagnostics Market?

The growing occurrence of cancer is anticipated to drive the expansion of the liquid biopsy for cancer diagnostics market in the future. Cancer refers to a wide range of diseases that can arise in almost any body organ or tissue, characterized by the uncontrolled multiplication of abnormal cells that surpass their normal limits and can spread to other organs or invade adjacent tissues. The prevalence of cancer heightens the demand for diagnostic methods like early detection of cancer or tumor recurrence, individual patient risk assessment, and treatment oversight. Liquid biopsy fulfills this need by illustrating the complete progression of the disease, as tumor cells or their byproducts are released from all primary or metastatic tumor sites, offering comprehensive and current data on tumor cell changes, therapeutic goals, and how tumors resist treatment. For example, data from May 2024, provided by the National Cancer Institute, a US-based government agency, indicated approximately 18.1 million cancer survivors in the United States. This number is projected to increase to 22.5 million by 2032. Furthermore, by 2040, new cancer diagnoses annually are anticipated to reach 29.9 million, with cancer-related fatalities expected to grow to 15.3 million. Consequently, the escalating incidence of cancer is a key factor propelling the expansion of the liquid biopsy for cancer diagnostics market.

How Is The Liquid Biopsy For Cancer Diagnostics Market Segmented Across Key Categories?

The liquid biopsy for cancer diagnostics market covered in this report is segmented –

1) By Type: Product, Services

2) By Sample: Blood, Urine, Saliva

3) By Cancer: Lung Cancer, Breast Cancer, Colon Cancer, Other Cancers

4) By End-User: Hospitals, Diagnostic Centers, Other End-Users

Subsegments:

1) By Product: Circulating Tumor Cells (CTCs) Detection Kits, Circulating Tumor DNA (ctDNA) Detection Kits, Exosome Isolation Kits, Sample Collection Devices

2) By Services: Testing Services, Analytical Services, Bioinformatics Services

What Industry Trends Are Redefining The Liquid Biopsy For Cancer Diagnostics Market?

Companies operating in the liquid biopsy for cancer diagnostics market are focusing their strategies on developing innovative solutions, including advanced liquid biopsy assays. An advanced liquid biopsy assay is a sophisticated and highly refined diagnostic test that examines various elements present in a liquid biological sample, such as blood or other bodily fluids, to detect and characterize particular biomarkers linked to cancer or other illnesses. For example, in November 2023, Illumina Inc., a US-based global leader in DNA sequencing, revealed the launch of ‘TruSight Oncology 500 ctDNA v2 (TSO 500 ctDNA v2)’. This is a research assay specifically designed to enable noninvasive comprehensive genomic profiling (CGP) of circulating tumor DNA (ctDNA) extracted from blood. The TSO 500 ctDNA v2 assay is intended to simplify integration for users and enhance the depth of insights available for cancer research efforts.

Who Are The Dominant Players Shaping The Liquid Biopsy For Cancer Diagnostics Market Landscape?

Major companies operating in the liquid biopsy for cancer diagnostics market are F. Hoffman La Roche Ltd., Thermo Fisher Scientific Inc., Agilent Technologies Inc., Illumina Inc., The Menarini Group, Bio-Rad Laboratories Inc., QIAGEN Inc., Exact Sciences Corporation, Bio-Techne Corporation, ArcherDX Inc., Neogenomics Laboratories Inc., Guardant Health Inc., Myriad Genetics Inc., Foundation Medicine Inc., Amoy Diagnostics Co. Ltd., Biocartis Group NV, Biodesix Inc., MDx Health Inc., Sysmex Inostics Inc., Biocept Inc., Agena Bioscience Inc., Laboratory for Advanced Medicine (LAM) Inc., MiRXES Pte Ltd., Inivata Limited, Resolution Bioscience Inc., SAGA Diagnostics AB, NuProbe Inc., Personal Gemone Diagnostics Inc., Pathway Genomics Corporation, Angle PLC

Read the full liquid biopsy for cancer diagnostics market report here:

https://www.thebusinessresearchcompany.com/report/liquid-biopsy-for-cancer-diagnostics-global-market-report

Which Region Currently Holds The Largest Share Of The Liquid Biopsy For Cancer Diagnostics Market?

North America was the largest region in the liquid biopsy for cancer diagnostics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the liquid biopsy for cancer diagnostics market report during the forecast period. The regions covered in the liquid biopsy for cancer diagnostics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Liquid Biopsy For Cancer Diagnostics Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=12205&type=smp

Browse Through More Reports Similar to the Global Liquid Biopsy For Cancer Diagnostics Market 2026, By The Business Research Company

Liquid Biopsy For Cancer Diagnostics Global Market Report

https://www.thebusinessresearchcompany.com/report/liquid-biopsy-for-cancer-diagnostics-global-market-report

Biopsy Devices Global Market Report

https://www.thebusinessresearchcompany.com/report/biopsy-devices-global-market-report

Biopsy Devices Global Market Report

https://www.thebusinessresearchcompany.com/report/biopsy-devices-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795